[{"id":"d0b024e8-77de-4ee7-8bba-6a54661e6118","acronym":"COTI2-101","url":"https://clinicaltrials.gov/study/NCT02433626","created_at":"2021-01-18T11:39:07.906Z","updated_at":"2024-07-02T16:37:03.257Z","phase":"Phase 1","brief_title":"Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies","source_id_and_acronym":"NCT02433626 - COTI2-101","lead_sponsor":"Critical Outcome Technologies Inc.","biomarkers":" TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • COTI-2"],"overall_status":"Unknown status","enrollment":" Enrollment 51","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-02-01"}]